Literature DB >> 15535988

Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia.

Scott D Campbell1, Sonia M de Morais, Jinghai J Xu.   

Abstract

OATP1B1 (a.k.a. OATP-C, OATP2, LST-1, or SLC21A6) is a liver-specific organic anion uptake transporter and has been shown to be a higher affinity bilirubin uptake transporter than OATP1B3. Using human embryonic kidney (HEK 293) cells stably transfected with OATP1B1, we have studied the effects of indinavir, saquinavir, cyclosporin A, and rifamycin SV on human OATP1B1 transport function. These drugs are potent inhibitors of OATP1B1 transport activity in vitro. We further provide evidence that the calculated fraction of OATP1B1 inhibited at the clinical exposure level correlated very well with the observed hyperbilirubinemia outcome for these drugs in humans. Our data support the hypothesis that inhibition of OATP1B1 is an important mechanism for drug-induced unconjugated hyperbilirubinemia. Inhibition of OATPs may be an important mechanism in drug-drug and drug-endogenous substance interactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15535988     DOI: 10.1016/j.cbi.2004.08.008

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  26 in total

1.  Comparison of intestinal absorption and disposition of structurally similar bioactive flavones in Radix Scutellariae.

Authors:  Chenrui Li; Li Zhang; Limin Zhou; Siu Kwan Wo; Ge Lin; Zhong Zuo
Journal:  AAPS J       Date:  2011-12-14       Impact factor: 4.009

Review 2.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Authors:  Megan Roth; Amanda Obaidat; Bruno Hagenbuch
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

4.  Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors.

Authors:  Dale J Kempf; Jeffrey F Waring; David C Morfitt; Paige Werner; Brian Ebert; Michael Mitten; Bach Nguyen; John T Randolph; David A DeGoey; Larry L Klein; Kennan Marsh
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3.

Authors:  Chunshan Gui; Yi Miao; Lucas Thompson; Bret Wahlgren; Melissa Mock; Bruno Stieger; Bruno Hagenbuch
Journal:  Eur J Pharmacol       Date:  2008-02-08       Impact factor: 4.432

6.  Bone mineral densities in individuals with Gilbert's syndrome: a cross-sectional, case-control pilot study.

Authors:  G Y Minuk; R Greenberg; J Uhanova; K Hawkins; W D Leslie
Journal:  Can J Gastroenterol       Date:  2009-06       Impact factor: 3.522

7.  HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis.

Authors:  Joel D Mermis; Steven Q Simpson
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

8.  HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.

Authors:  Ruben C Hartkoorn; Wai San Kwan; Victoria Shallcross; Ammara Chaikan; Neill Liptrott; Deirdre Egan; Enrique Salcedo Sora; Chloë E James; Sara Gibbons; Pat G Bray; David J Back; Saye H Khoo; Andrew Owen
Journal:  Pharmacogenet Genomics       Date:  2010-02       Impact factor: 2.089

9.  Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP).

Authors:  Zhongqi Dong; Sean Ekins; James E Polli
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

Review 10.  Impact of OATP transporters on pharmacokinetics.

Authors:  A Kalliokoski; M Niemi
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.